27,980 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Acquired by Natixis Advisors LLC

Natixis Advisors LLC acquired a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 27,980 shares of the company's stock, valued at approximately $1,621,000. Natixis Advisors LLC owned approximately 0.06% of Astrana Health as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ASTH. SteelPeak Wealth LLC purchased a new position in Astrana Health during the 3rd quarter valued at approximately $39,398,000. NorthCrest Asset Manangement LLC bought a new stake in Astrana Health in the third quarter worth $26,704,000. Principal Financial Group Inc. purchased a new stake in Astrana Health during the third quarter valued at $13,383,000. F M Investments LLC bought a new position in Astrana Health during the third quarter valued at $11,738,000. Finally, Diamond Hill Capital Management Inc. purchased a new position in shares of Astrana Health in the 3rd quarter worth $8,245,000. 52.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ASTH. KeyCorp started coverage on shares of Astrana Health in a research report on Friday, October 11th. They set a "sector weight" rating on the stock. Robert W. Baird raised their price objective on Astrana Health from $67.00 to $86.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. TD Cowen began coverage on Astrana Health in a report on Monday, October 14th. They issued a "buy" rating and a $66.00 target price for the company. Stifel Nicolaus increased their price target on Astrana Health from $48.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, August 1st. Finally, BTIG Research lifted their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, October 3rd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $65.17.

Astrana Health Trading Down 0.4 %

ASTH traded down $0.15 during trading hours on Tuesday, reaching $42.25. 195,514 shares of the company's stock traded hands, compared to its average volume of 209,933. The firm has a 50-day moving average price of $53.91 and a 200 day moving average price of $47.96. The firm has a market capitalization of $2.38 billion, a PE ratio of 32.71, a PEG ratio of 1.95 and a beta of 1.24. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a 52-week low of $32.32 and a 52-week high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.33. The firm had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period in the previous year, the firm earned $0.47 earnings per share. As a group, sell-side analysts predict that Astrana Health, Inc. will post 1.17 EPS for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.